GlassScriptPhysician profile
Luz A Moreno
NPI 1790751592
$693.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $69.37 · 2021: $199 · 2022: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.36 | 2019-2022 | |
| Vifor Pharma, INC. | $129.39 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $124.13 | 2022 | |
| Horizon Therapeutics Plc | $47.43 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $37.89 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $37.59 | 2019-2022 | |
| Novo Nordisk INC | $30.85 | 2021 | |
| Aurinia Pharma U.S., INC. | $27.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.09 | 2019 | |
| Medtronic USA, INC. | $22.38 | 2020 | |
| Akebia Therapeutics INC | $15.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2022 | |
| Shield Therapeutics INC | $14.68 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.